Industry News

Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.

Emcure Pharmaceuticals Ltd. announced robust financial results for the third quarter of the 2025-26 fiscal year, marking significant growth across both domestic and international businesses. The company reported a notable rise in profitability and topline performance, underpinned by diversified portfolio strength and strategic initiatives.

British pharmaceutical firm AstraZeneca PLC announced on Thursday it will commit usd 15 billion (about ₹1.2 lakh crore) to expand research, development and manufacturing operations in China through 2030, underscoring the country’s growing importance in global drug innovation and production.

The investment, detailed in a company press release, aims to bolster AstraZeneca’s capabilities across the entire drug value chain from discovery and clinical development to large-scale manufacturing, particularly in cell therapies and radioconjugates, two areas of rapid scientific advance.